ESMO Highlights: Urothelial Cancer

Ramucirumab plus Docetaxel Superior to Docetaxel Monotherapy in Platinum-Refractory Advanced Urothelial Cancer

Phoebe Starr

December 2017, Vol 7, No 12 - ESMO Highlights: Urothelial Cancer

Ramucirumab (Cyramza), a vascular endothelial growth factor receptor 2 inhibitor, added to docetaxel improved progression-free survival (PFS) and nearly doubled the objective response rate (ORR) compared with docetaxel monotherapy in patients with advanced or metastatic urothelial cancer that progressed with platinum-based chemotherapy in the phase 3 RANGE clinical trial. This is the first phase 3 clinical trial to show a PFS advantage over chemotherapy alone in this setting. Lead investigator Daniel P. Petrylak, MD, Professor of Medicine and of Urol­ogy, Yale School of Medicine and Yale Cancer Center, New Haven, CT, presented the results at the 2017 European Society for Medical Oncology (ESMO) Congress. [ Read More ]